

Commissioner of Patents
USSN 10/661,402

REMARKS

Claims 52-56 are pending in the application. Claims 1-51 and 57 have been previously withdrawn.

Claim rejections - 35 U.S.C. § 102

The Examiner maintains her rejection of claims 52-56 under 35 U.S.C. 102(e) as being anticipated by Peyman *et al.* The Examiner mentioned that the response submitted September 8, 2006, with respect to the fact that Peyman *et al.* only teaches that the efficacy of the tested oligonucleotides is dependent on the presence of 10 guanines extension at each extremity of the oligonucleotide, was not convincing. The Examiner alleged that this argument relates to the G-quartet structures which are not mentioned in the claims. Furthermore, the Examiner alleged that Peyman *et al.* teaches administering the same oligonucleotides as those of the claimed invention (oligonucleotides of at least 10 nucleotides in length) and teaches administering the oligonucleotides to the same patient population as the present invention. Therefore, since Peyman teaches administering the same composition to the same patient population, the method of Peyman anticipates the claimed invention. The Examiner concluded that the oligonucleotide composition of Peyman has antiviral activity acting by a sequence independent mode of action.

In order to overcome this rejection, Applicants respectfully submit that nowhere is it taught or even suggested in Peyman *et al.* that oligonucleotides have antiviral activity against multiple viruses acting by a sequence independent mode of action. Moreover, Peyman *et al.* is only enabled for four antisense oligonucleotides against HSV-1 in cell culture (as disclosed in column 14, lines 14-19 in Peyman). Peyman *et al.* only teaches how to stabilize and improve cell penetration by capping oligonucleotides (with the addition of a cap of guanine at their extremities). When considering the sequences disclosed by Peyman *et al.*, all of the sequences disclosed therein are antisenses. Moreover, Peyman *et al.* in column 6, lines 8-9 teaches that the effective oligonucleotides are understood to mean antisense oligonucleotides. By definition, an "antisense" is a molecule that interacts with complementary strands of nucleic acids, modifying the expression of genes. Consequently, a person skilled in the art would recognize that an antisense RNA or single-stranded antisense DNA is a molecule which is complementary to the nucleic acid sequence of a gene of interest. Thus, the

Commissioner of Patents
 USSN 10/661,402

mechanism of action of an antisense is sequence dependent since it must be complementary to a strand of nucleic acids in order to interact and modify the expression of the gene of interest. In addition, such person skilled in the art would come to the conclusion that SEQ ID NOs: 1-34 represent sequences that are complementary to a known gene, and thus represent possible antisense oligonucleotides. The following Table identifies the gene targeted by these antisenses:

| Patent Seq ID | Sequence | Homologous to (% coverage) | Accession # |
|---------------|------------------------------|--|----------------|
| 1 | ACACCCAATTCTGAAAATGG | HIV-1, complete genome (100) | AF003819.3 |
| 2 | AGGTCCTGTTCGGGCGCCA | HIV-1 proviral DNA, complete genome (100) | AB289588.1 |
| 3 | GTCGACACCCAATTCTGAAAATGGATAA | HIV-1, complete genome (100) | AF003819.3 |
| 4 | GCTATGTCGACACCCAATTCTGAA | HIV-1 proviral DNA, complete genome (100) | AB287367.1 |
| 5 | GTCGCTGTCTCCGCTTCTTCTTCCTG | HIV-1 isolate B055AA from USA tat protein (tat) gene, partial cds (100 [bases 1-22]) | AY734162.1 |
| 6 | GTCTCCGCTTCTTCTTCTGCCA TAGG | HIV-1 proviral DNA, complete genome (100 [bases 10-27]) | AB289588.1 |
| 7 | GCGGGGCTCCATGGGGGTCG | Human herpesvirus 1 complete genome (100) | X14112.1 |
| 8 | CAGCTGCAACCCAGC | Homo sapiens angiomin like 1 (AMOF1), mRNA (100) | NM_130847.2 |
| 9 | GGCTGCTGGAGCGGGGCACAC | Homo sapiens MYC gene for c-myc proto-oncogene and ORF1 (100) | X00364.2 |
| 10 | AACGTTGAGGGGCAT | Homo sapiens v-myc myelocytomatosis viral oncogene homolog (100) | NM_002467.3 |
| 11 | GTGCCGGGGTCTTCGGGC | Homo sapiens mRNA for v-myb myeloblastosis viral oncogene (100) | AJ616235.1 |
| 12 | GGAGAACATCATGGTCGAAAG | Mouse c-fos oncogene (100) | V00727.1 |
| 13 | CCCGAGAACATCATGGTCGAAG | Mouse c-fos oncogene (100) | V00727.1 |
| 14 | GGGGAAGCCCGGCAAGGGG | Mouse c-fos oncogene (100) | V00727.1 |
| 15 | CACCCGCCCTGGCCTCCAC | Multiple human genomic hits (100) | |
| 16 | GGGACTCCGGCGCAGCGC | Human mRNA for precursor of epidermal growth factor receptor (100) | X00588.1 |
| 17 | GGCAAACCTTCTTTCTCTCC | Homo sapiens epidermal growth factor receptor (100) | NM_201284.1 |
| 18 | GGGAAGGAGGAGGATGAGG | Mus musculus mRNA for p53, complete cds (100) | AB020317.1 |
| 19 | GGCAGTCATCCAGCTCGGAG | Mouse mRNA for transformation associated protein p53 (100) | X00741.1 |
| 20 | GCAGTAAGCATCCATATC | Felis catus integrin beta 1 (100) | NM_001048160.1 |
| 21 | CCCCCACCACCTCCCTCTC | Homo sapiens intercellular adhesion molecule 1 (100) | BC015969.2 |
| 22 | CTCCCCCACCACCTCCCTCTC | Homo sapiens intercellular adhesion molecule 1 (100) | BC015969.2 |
| 23 | GCTGGGAGCCATAGCGAGG | Homo sapiens intercellular adhesion molecule 1 (100) | BC015969.2 |
| 24 | ACTGCTGCCTCTTGTCTCAGG | Homo sapiens HES2 gene (100 [bases 2-16] and multiple genomic hits (100) | NM_019089.3 |
| 25 | CAATCAATGACTTCAAGAGTTC | Homo sapiens selectin E (endothelial adhesion molecule 1) [bases 7-22] and multiple genomic hits (100) | NM_000450.1 |
| 26 | GGTCCCTGTTCGGGCGCCA | HIV-1 proviral DNA, complete genome (100) | AB289588.1 |
| 27 | GTGCCGGGGTCTTCGGG | Homo sapiens mRNA for v-myb myeloblastosis viral oncogene (100) | AJ616235.1 |

Commissioner of Patents
USSN 10/661,402

| Patent Seq ID | Sequence | Homologous to (% coverage) | Accession # |
|---------------|---------------------|---|-------------|
| 28 | GGAGGATGCTGAGGAGG | Human herpesvirus 1 gene for DNA polymerase UL30 (100) | AB231460.1 |
| 29 | GGAGGATGCTGAGG | Human herpesvirus 1 gene for DNA polymerase UL30 (100) | AB231460.1 |
| 30 | CAGGAGGATGCTGAGGAGG | Human herpesvirus 1 gene for DNA polymerase UL30 (100) | AB231460.1 |
| 31 | GGCTGCCATGGTCCC | Homo sapiens fibroblast growth factor 2 (100) | NM_002006.3 |
| 32 | TCATGGTGTCTTTGCAGCC | Homo sapiens procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (100 [bases 1-15] and multiple genomic hits (100) | NM_001084.4 |
| 33 | TCATGGTGTCTTTGCAG | Homo sapiens procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (100 [bases 1-15] and multiple genomic hits (100) | NM_001084.4 |
| 34 | AAGTTCATGGTTTCGG | Homo sapiens vascular endothelial growth factor A (100) | NM_003376.4 |

In column 6, lines 30-31; column 8, lines 29-30; column 10, lines 35-36; column 11, lines 4-5; and column 14, lines 14-19 of Peyman *et al.*, it is clearly stated that the following oligonucleotides are examples of novel antisense effective against the following targets:

| SEQ ID NOs | Target gene |
|------------|----------------------|
| 35-46 | HIV |
| 47-54 | HSV-1 |
| 55-56 | c-Ha-ras |
| 57-60 | c-myc |
| 61-63 | c-myb |
| 64-70 | c-fos |
| 71-72 | p120 |
| 73-77 | EGF receptor |
| 78-81 | p53 tumor suppressor |
| 82-83 | bFGF |
| 84 | VEGF |
| 85-86 | VLA-4 |
| 87-94 | ICAM |
| 95-98 | ELAM-1 |
| 99-103 | TNF-alpha |
| 104-105 | HSV-1 |

Consequently, SEQ ID NOs: 1-105 all represent antisense oligonucleotides which are complementary to a portion of the nucleic acid sequence of a specific gene. Thus, by its inherent properties, as well as by definition, an antisense will modify the expression of a gene by a sequence dependent mode of action. The present application teaches oligonucleotides having a sequence independent mode of action. For example, with random oligonucleotides, as taught in the present description, due to the nature of the preparation

Commissioner of Patents
USSN 10/661,402

used to produce them, a sequence complementary mode of action cannot occur. On page 34 of the present description, it is clearly disclosed that for a randomer oligonucleotide of 40 bases in length, any particular sequence in the population would theoretically represent only $1/4^{40}$ or 8.27×10^{-25} of the total fraction. Given that 1 mole = 6.022×10^{23} molecules, and the fact that the largest synthesis is currently done on a 15 micromole scale, all possible sequences will not be present. Also, there is most probably only one copy of each sequence. Consequently, by its inherent properties, the mode of action of these oligonucleotides is sequence independent and does not require complementarity to the nucleic acid sequence of a gene.

In addition, it is clearly stated in Peyman *et al.* (column 1 and 2, under the Summary section), that:

"It has now been found that a very simple option exists for significantly improving unmodified or modified oligonucleotides with regards to their nuclease resistance and cell penetration, so that their activity is substantially improved, by extending the oligonucleotides at the 3' end and/or 5' end by from one to 10 guanines.

Surprisingly, the novel oligonucleotide also exhibit a tendency to associate or aggregate. It is possible that they too form G quartet structures by the association of two or more oligonucleotide. Such structures would protect against exonuclease degradation and lead to an increased uptake in cell."

Thus, Peyman *et al.* discloses and claims antisenses which are complementary to a target sequence and which have a Cap of guanine(s) at its 5' and/or 3' extremity. Nowhere in the present application is it taught, claimed or required that the oligonucleotides of the present invention need to possess a Cap of guanines in order to increase its nuclease resistance and cell penetration, or that they be antisense or have sequence complementarity to a target so that their activity will be improved. Again, a person skilled in the art would recognize that Peyman *et al.* teaches antisense oligonucleotides wherein the stabilized antiviral activity depends on the presence of a Cap of guanines. Thus, the stabilization of the antisenses disclosed in Peyman is dependent on the presence of a secondary structure since,

Commissioner of Patents
USSN 10/661,402

as stated in Peyman *et al.* (see column 1, lines 55-57), oligonucleotides which contain short segments of G residues are able to form intramolecular structures called G-quartets. Thus, not only is the antiviral activity dependent on the sequence, but the stabilization of the antisenses disclosed in Peyman is sequence dependent (in order to form the G-quartet structure).

In view of the arguments presented hereinabove, it is believed that the claims now on file are novel and inventive in view of the teaching of Peyman *et al.*, and thus reconsideration and withdrawal of the Examiner's rejection are earnestly solicited.

Double Patenting

Claims 52-56 have been provisionally rejected on the grounds of non-statutory obviousness-type double patenting over claims 53-57 of co-pending Application No. 10/969,812. In order to overcome this rejection, enclosed herewith is a Terminal Disclaimer under 37 C.F.R. §1.321. It is believed that with such a Terminal Disclaimer on file, rejection under double-patenting is moot.

It is submitted, therefore, that the claims are now in condition for allowance. Reconsideration of the Examiner's rejections is respectfully requested. Allowance of claims 52-56 at an early date is solicited.

No additional fees are believed to be necessitated by this amendment. Should this be in error, authorization is hereby given to charge Deposit Account No. 19-5113 for any underpayment or to credit any overpayment.

In the event that there are any questions concerning this amendment or the application in general, the Examiner is respectfully urged to telephone the undersigned so that prosecution of this application can be expedited.

Commissioner of Patents
USSN 10/661,402

Respectfully,

Date: April 11, 2007

By: 

Christian Cawthorn, Reg. No. 47,352
Agent for Applicants

OGILVY RENAULT
1981 McGill College, Suite 1600
Montreal, Quebec H3A 2Y3
CANADA (514) 847-4256

Enc. Petition for extension of time
Terminal disclaimer